Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Mobocertinib Elicits Anticancer Activity in Platinum-Pretreated EGFR Exon 20 Insertion+ Advanced NSCLC

June 4th 2021

Mobocertinib, a first-in-class, oral, EGFR TKI, induced rapid, deep, and durable responses and a manageable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Concurrent Pembrolizumab Plus Chemoradiation Therapy Elicits Antitumor Activity in NSCLC

June 4th 2021

Pembrolizumab plus concurrent chemoradiation therapy induced antitumor effects in patients with unresectable, locally advanced, stage III non–small cell lung cancer irrespective of PD-L1 expression or tumor histology.

Brigatinib Maintains Long-Term Efficacy in Crizotinib-Refractory ALK+ NSCLC

June 4th 2021

Brigatinib demonstrated sustained long-term responses and survival in patients with crizotinib-refractory ALK-positive non–small cell lung cancer.

Pralsetinib Is Tolerable, Durable in RET Fusion-Positive NSCLC

June 4th 2021

Updated findings from the ARROW trial demonstrated that pralsetinib could benefit those with RET fusion–positive non–small cell lung cancer and is a well-tolerated agent in the patient population.

Surgical Resectability in Stage IIIA-N2 NSCLC

June 3rd 2021

Christian Grohé, MD, and Gary Doherty, MRCP, PhD, consider factors that may influence the resectability of patients with stage IIIA-N2 disease, such as biomarker status, performance status, and imaging results.

Potential Challenges of Molecular Testing in NSCLC

June 3rd 2021

A panel of experts in the management of lung cancer share key insights into challenges associated with retesting for driver mutations, tumor heterogeneity, and potential differences between biopsy and surgical sample test results.

Dr. Lilenbaum on the Clinical Implications of the FDA Approval of Lurbinectedin in SCLC

June 2nd 2021

Rogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.

Nivolumab/Ipilimumab Approved in Europe for Frontline Unresectable Malignant Pleural Mesothelioma

June 2nd 2021

The European Commission has approved the dual immunotherapy combination of nivolumab and ipilimumab for use in the frontline treatment of adults with unresectable malignant pleural mesothelioma.

Dr. Ross on Toxicity Concerns With Combination Therapies in EGFR+ NSCLC

June 1st 2021

Helen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.

FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC

May 28th 2021

The FDA has approved sotorasib as the first treatment for adult patients with non–small cell lung cancer whose tumors harbor KRAS G12C mutations and who have received at least 1 prior systemic therapy.

Key to Leveraging Emerging Approaches in Lung Cancer Lies in Balancing Benefit With Risk

May 28th 2021

Novel immunotherapy combinations are gaining ground in the frontline treatment of patients with lung cancer, but the toxicities associated with these regimens must be weighed against the benefit they provide.

Adjuvant Osimertinib Approved in Europe for Early-Stage EGFR+ NSCLC

May 28th 2021

The European Commission has approved osimertinib for the adjuvant treatment of adult patients with early-stage EGFR-mutated non–small cell lung cancer following complete resection with curative intent.

Sugemalimab Shows Prolonged PFS in Stage III NSCLC

May 28th 2021

The investigational PD-L1 inhibitor sugemalimab prolonged progression-free survival in patients with locally advanced, unresectable stage III non–small cell lung cancer without disease progression after concurrent or sequential chemoradiation.

Real-World Data Reflect Shorter Survival With Pembrolizumab in Older NSCLC Population

May 28th 2021

Pembrolizumab alone and in combination with chemotherapy was associated with shorter overall survival compared with the data demonstrated in the registrational clinical trials in older Medicare patients with advanced non–small cell lung cancer, providing real-world insight into the prognosis of older patients with NSCLC who are treated with immunotherapy.

A Multidisciplinary Approach to Reflex Testing in NSCLC

May 27th 2021

Gary Doherty, MRCP, PhD, and Christian Grohé, MD, discuss the multidisciplinary approach to molecular testing for EGFR mutations in NSCLC and the importance of reflex testing to limit delays in receiving results.

Dr. Niu on Treatment Updates in RET+/KRAS+ NSCLC

May 27th 2021

Jason Niu, MD, PhD, discusses treatment updates in RET fusion–positive and KRAS-mutant non–small cell lung cancer.

Molecular Testing in Resectable NSCLC

May 27th 2021

Solange Peters, MD, PhD, reviews factors to consider for molecular testing in early stage non–small cell lung cancer and discusses the role of single-gene assays and next-generation sequencing panels.

Dr. Socinski on the Utility of ctDNA Testing in Lung Cancer

May 26th 2021

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

Dr. Bardoni on the Importance of the LIBRETTO-001 Trial With Selpercatinib in RET+ NSCLC

May 26th 2021

Rodolfo Bordoni, MD, discusses the importance of the phase 1/2 LIBRETTO-001 trial with selpercatinib in patients with RET fusion–positive non–small cell lung cancer.

Neoadjuvant Nivolumab/Ipilimumab Enhances Pathologic Responses in Resectable NSCLC

May 26th 2021

The addition of neoadjuvant ipilimumab to nivolumab resulted in higher rates of major pathologic response and pathologic complete response, while enhancing tumor immune cell infiltrates in patients with resectable non–small cell lung cancer, according to data from the phase 2 NEOSTAR trial.